| 24.09 07:30 | dpa-AFX: Biogen: Phase 3 PHOENYCS GO Study With Dapirolizumab Pegol Meets Primary Endpoint |
| 24.09 07:05 | dpa-AFX: *UCB AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 PHOENYCS GO STUDY OF DAPIROLIZUMAB PEGOL |
| 24.09 07:00 | dpa-AFX: GNW-Adhoc: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 |
| 20.09 14:33 | dpa-AFX: Samsung Bioepis, Biogen Announce Positive CHMP Recommendation For OPUVIZ In Europe |
| 20.09 14:12 | dpa-AFX: *SAMSUNG BIOEPIS AND BIOGEN OBTIN POSITIVE CHMP OPINION FOR AFLIBERCEPT BIOSIMILAR, OPUVIZ |
| 12.09 14:49 | dpa-AFX: *BIOGEN APPOINTS LLOYD B. MINOR AND MENELAS (MENE) PANGALOS TO BOARD |
| 12.09 13:30 | dpa-AFX: GNW-Adhoc: Biogen Board Appoints Two New Independent Directors |
| 04.09 14:16 | dpa-AFX: Biogen Reports Positive Topline Data From DEVOTE Study Of Higher Dose Regimen Of Nusinersen In SMA |
| 04.09 13:40 | dpa-AFX: *BIOGEN ANNOUNCES POSITIVE RESULTS FROM PHASE 2/3 STUDY OF HIGHER DOSE REGIMEN OF NUSINERSEN IN SMA |
| 04.09 13:30 | dpa-AFX: GNW-Adhoc: Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA |
| 23.08 22:12 | dpa-AFX: UK Health Regulator Disapproves Leqembi's Approval For Treatment Of Early Alzheimer's |
| 22.08 11:54 | dpa-AFX: Eisai And Biogen : Leqembi Approved In Great Britain For Early Alzheimer's Disease |
| 22.08 11:15 | dpa-AFX: *EISAI, BIOGEN: LEQEMBI HAS BEEN GRANTED MARKETING AUTHORIZATION BY MHRA FOR EARLY ALZHEIMER'S DISEASE IN GREAT BRITAIN |
| 04.08 11:00 | dpa-AFX: Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid |
| 02.08 13:48 | dpa-AFX: *DZ BANK RAISES FAIR VALUE FOR BIOGEN TO 219 (214) USD - 'HOLD' |
| 02.08 13:48 | dpa-AFX: *DZ BANK HEBT FAIREN WERT FÜR BIOGEN AUF 219 (214) USD - 'HALTEN' |
| 01.08 13:31 | dpa-AFX: Biogen Q2 Results Top Estimates; Boosts FY24 Outlook |
| 01.08 13:17 | dpa-AFX: *BIOGEN Q2 TOTAL REVENUE $2.465 BLN; NET INCOME ATTRIBUTABLE TO BIOGEN $583.6 MLN |
| 01.08 13:16 | dpa-AFX: *BIOGEN NOW SEES FY OPERATING INCOME TO GROW AT A MID- TO HIGH-TEEN PERCENTAGE |
| 01.08 13:15 | dpa-AFX: *BIOGEN NOW SEES FY TOTAL REVENUE TO DECLINE BY A LOW-SINGLE DIGIT PERCENTAGE |
|
|
